Its announcement will come on the heels of an analogous licensing arrangement presented in February to Adastra Labs, which had until finally now focused on crafting cannabis extracts. Adastra's license also enables it to create and market psilocybin and psilocin – hallucinogens much more usually often called magic mushrooms that generate conseque